Diabetes is a growing epidemic in the United States, affecting an estimated 30.3 million people, or nearly one-tenth of the population. Recently updated guidelines advocate the use of a wider range of treatments and combinations to individualize therapy for patients with type 2 diabetes (T2D).
This calls for physicians to tailor patien tspecific treatment plans by combining agents with complementary mechanisms of action to achieve and maintain glycemic control. In addition, patients with T2D are at high risk for atherosclerotic cardiovascular (CV) complications. Therefore, antihyperglycemic agents that not only improve hyperglycemia but also reduce CV risk are desirable.
In this activity, experts in the field of diabetes will review the role of centrally acting medications in the treatment of T2D.
Upon completion of this activity, learners will have increased knowledge regarding the
- Mechanism of action of centrally acting treatments for diabetes
- Role of centrally acting pharmacologic therapy in diabetes management
- Patient education points related to bromocriptine and diabetes treatment
And have greater competence related to
- The use of a comprehensive management plan for patients with diabetes
- The appropriate use of centrally acting pharmacologic therapy as part of an individualized diabetes management plan
This activity is intended for diabetologists and endocrinologists.